Drug Profile
P4 - Cenna Biosciences/University of California, San Diago
Alternative Names: P-4Latest Information Update: 28 Aug 2020
Price :
$50
*
At a glance
- Originator Cenna Biosciences; University of California, San Diego
- Class Antidementias; Peptide fragments
- Mechanism of Action Amyloid beta-protein precursor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA
- 29 Jul 2016 Preclinical trials in Alzheimer's disease in USA (unspecified route)